Clinical and economic outcomes of adding durvalumab to gemcitabine/cisplatin in advanced biliary tract cancers: A multicenter descriptive study
This study confirms effectiveness of durvalumab, aligning with clinical trial results. However, the substantial economic burden underscores the importance of optimizing dosing strategies. The recent approval of pembrolizumab further highlights the need for prospective cost-benefit comparisons studies incorporating predictive biomarkers.
Authors
- Florian Slimano (ORCID: https://orcid.org/0000-0001-5139-7034)
- Claire Carlier (ORCID: https://orcid.org/0000-0002-9889-1424)
- Elia Gigante (ORCID: https://orcid.org/0000-0002-5455-2308)
- Justine Clarenne (ORCID: https://orcid.org/0000-0001-8400-2174)
- Marine Perrier (ORCID: https://orcid.org/0000-0002-4528-5471)
- Lorenzo Luciani (ORCID: https://orcid.org/0000-0002-0200-895X)
- Olivier Bouché (ORCID: https://orcid.org/0000-0002-8284-3743)
- V. Lepage (ORCID: https://orcid.org/0000-0003-1876-1599)
- Léonie Leuk
Institutions
- Centre Hospitalier Universitaire de Reims (FR)
- Université de Reims Champagne-Ardenne (FR)
Publication Details
- Journal
- Clinics and Research in Hepatology and Gastroenterology
- Published
- 2025-11-20
- DOI
- https://doi.org/10.1016/j.clinre.2025.102733
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00